SCHEMBL7332181

SCHEMBL7332181

CCCC1NS(=O)(=O)N(Cc2ccccc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
GAA P10253 5/20 0.39
CYP2C19 P33261 4/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
POLB P06746 2/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
EHMT2 Q96KQ7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
PAX8 Q06710 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7328442 0.75 ALDH1A1 (0.51) KMT2ACA12CA9GAACYP2C19
SCHEMBL7441176 0.74 GAA (0.41) KMT2AGAACYP2C19ALDH1A1CYP1A2
SCHEMBL7335115 0.72 ELANE (0.53) KMT2ACA12CA9GAACYP2C19
SCHEMBL7462751 0.71 GAA (0.41) GAACYP2C19ALDH1A1CYP1A2CYP2C9
SCHEMBL7339586 0.70 KMT2A (0.44) KMT2ACA12CA9GAACYP2C19
SCHEMBL17676971 0.69 EHMT2 (0.42) KMT2AGAAALDH1A1POLBMEN1
SCHEMBL23040155 0.68 MMP1 (0.46) KMT2AGAAALDH1A1MEN1SMN1; SMN2
SCHEMBL29270897 0.68 MMP1 (0.46) KMT2AGAAALDH1A1MEN1SMN1; SMN2
SCHEMBL29270895 0.68 MMP1 (0.46) KMT2AGAAALDH1A1MEN1SMN1; SMN2
SCHEMBL1714131 0.68 OPRK1 (0.57) KMT2AGAAALDH1A1MEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5750546-A SERINE PROTEASE INHIBITOR EFFECTIVE AGAINST DEGENERATIVE DISEASES, I.E., RESPIRATORY SYSTEM DISORDERS, RHEUMATOID ARTHRITIS SANOFI WINTHROP, INC. (US) 1998-05-12 US disclosed
EP-0792150-A4 2-(2,3,5,6-TETRAFLUORO-4-PYRIDYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP INC (US) 1998-03-11 EP disclosed
EP-0793494-A4 2-HETEROCYCLYLOXY AND THIOMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP INC (US) 1998-01-28 EP disclosed
EP-0793494-A1 2-HETEROCYCLYLOXY AND THIOMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1997-09-10 EP disclosed
EP-0792150-A1 2-(2,3,5,6-TETRAFLUORO-4-PYRIDYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1997-09-03 EP disclosed
US-5602154-A ADMINISTERING AN ENZYME INHIBITOR TREATING DEGENERATIVE DISEASES SANOFI WINTHROP, INC. (US) 1997-02-11 US disclosed
US-5556909-A PROTEOLYTIC ENZYME INHIBITOR, TREATMENT OF DEGENERATIVE DISEASES, SUCH AS EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS SANOFI WINTHROP INC. (US) 1996-09-17 US disclosed
US-5541168-A PROTEOLYTIC ENZYME INHIBITORS; DEGENERATIVE DISEASES; RESPIRATORY, SKIN, GENETIC AND GASTROINTESTINAL DISORDERS; ANTIARRTHRITIC AND -INFLAMMATORY AGENTS; GENETIC DISEASES STERLING WINTHROP INC. (US) 1996-07-30 US disclosed
WO-1996016654-A1 2-(2,3,5,6-TETRAFLUORO-4-PYRIDYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 WO disclosed
WO-1996016649-A1 2-HETEROCYCLYLOXY AND THIOMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 WO disclosed
WO-1996016970-A1 SUBSTITUTED 2-(PHOSPHINYLOXYMETHYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 WO disclosed
US-5494925-A TREATING DEGENERATIVE DISORDERS; PROTEOLYTIC ENZYME INHIBITOR STERLING WINTHROP INC. (US) 1996-02-27 US disclosed